CANNABIS pharmaceutical company Creso Pharma (ASX: CPH) has broken into the UK market with its new CannaQIX product, a losenge that works to reduce stress and support other mental and nervous functions.
Creso has partnered with UK-based Precision Healthcare to deliver the hemp-based drug in pharmacies and health food stores throughout the country.
The move follows Creso's foray into Europe in December 2017 when it signed a 10-year distribution deal with Doetsch Grether to market CannaQIX throughout Switzerland and Lichtenstein.
Creso will distribute to the UK from its base of operations in Swizterland, now that Swiss regulatory authorities have issued a certificate of free sales for exporting.
The company is now poised to continue building its operations in Europe and its CEO and co-founder Dr Miri Halperin Wernli is proud of its recent progress.
"We are delighted to partner with Precision Healthcare and to have obtained the necessary regulatory approvals for CannaQIX in the UK; both significant milestones for our company," she says.
CannaQIX technology uses capsicum to accelerate blood circulation in the mouth which enhances the delivery of cannabidiol, vitamins and zinc into the bloodstream.
The product is reportedly safe and well tolerated, as well as being non-euphoric, non-addictive and sugar free.
CannaQIX is currently sold as a food supplement with broad market reach and no medical prescription necessary to buy.
Following this morning's announcement, CPH shares are trading up 4.6 per cent at $1.12 at the time of writing (10:07am AEST).Never miss a news update, subscribe here. Follow us on Facebook, LinkedIn, Instagram and Twitter.
Business News Australia
Get our daily business news
Sign up to our free email news updates.
Help us deliver quality journalism to you.
As a free and independent news site providing daily updates
during a period of unprecedented challenges for businesses everywhere
we call on your support